ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

florbetaben f-18

Also written as “Florbetaben (BAY94-9172)”, “[18F]florbetaben” and “Florbetaben F18”.

Its studies are mostly in Alzheimer Disease · Amyloid Neuropathies, Familial · Down Syndrome, led by 2 companies.

Drug pageFlorbetaben f-18: every studyAll 15 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Feb 4, 20168 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lantheusits history only70 open or runningphase 4since Feb 4, 2016Sep 9, 2008none ahead
Sinotau Pharmaceutical Group10 open or runningno phasesince Aug 8, 2022Aug 8, 2022none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sinotau Pharmaceutical Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 8, 2022First study: no phase study in Alzheimer DiseaseFirst studyNCT05527288 · 50 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Sinotau Pharmaceutical Group leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05527288Alzheimer Disease · China–CompletedSep 12, 202150

How it is read

Names in the registry

  • “Florbetaben (BAY94-9172)”, 4 entries
  • “[18F]florbetaben”, 1 entry
  • “Florbetaben F18”, 1 entry
  • “Neuraceq (florbetaben 18F)”, 1 entry
  • “Drug: [18F]florbetaben”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.